Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.33 |
| ▸ | VCP | P55072 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | HPGDS | O60760 | 1/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.32 |
| ▸ | NCF1 | P14598 | 1/20 | 0.32 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22520690 | 0.94 | HRH3 (0.40) | HRH3ALDH1A1CYP1A2VCPCYP2D6 | |
| SCHEMBL22520616 | 0.87 | CHRM5 (0.40) | HRH3ALDH1A1NCF1ACHE | |
| SCHEMBL13741206 | 0.87 | HRH3 (0.45) | HRH3ALDH1A1CYP1A2VCPCYP2D6 | |
| SCHEMBL24475343 | 0.86 | HRH3 (0.39) | HRH3ALDH1A1CYP1A2VCPCYP2D6 | |
| SCHEMBL6448305 | 0.83 | NCF1 (0.43) | HRH3ALDH1A1CYP1A2CYP2D6HPGDS | |
| SCHEMBL12026484 | 0.82 | CYP1A2 (0.43) | HRH3CYP1A2VCP | |
| SCHEMBL23317131 | 0.82 | ALDH1A1 (0.44) | HRH3ALDH1A1CYP1A2CYP2D6HPGDS | |
| SCHEMBL21794544 | 0.80 | VCP (0.43) | HRH3VCPCYP2D6NCF1ACHE | |
| SCHEMBL22520695 | 0.79 | HRH3 (0.40) | HRH3ALDH1A1EHMT2ACHE | |
| SCHEMBL3437028 | 0.78 | CYP1A2 (0.48) | HRH3CYP1A2NCF1ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220169643-A1 | ESTROGEN RECEPTOR DEGRADING PROTACS | ASTRAZENECA UK LIMITED (GB) | 2022-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220169643-A1 | ESTROGEN RECEPTOR DEGRADING PROTACS | ESR1, GPER1, ESRRG | HRH3 1546/4885ALDH1A1 1242/4885CYP1A2 467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.